Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rommer

Showing results (161-170 of 220) with videos related to

Pageof 22
Sort By:
Multiple Sclerosis and Related Disorders|January 29, 2022
Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in GermanyJakob Holstiege, Manas K Akmatov, Kerstin Klimke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2022
Olfactory threshold predicts treatment response in relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Klaus Berek, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Therapeutic Advances in Chronic Disease|August 11, 2021
Rituximab <i>versus</i> mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosisTobias Zrzavy, Esther Daniels, Niklas Stuka, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 22, 2015
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)P S Rommer, T Dörner, K Freivogel, et al.
Brain Communications|November 12, 2025
Dynamic relationship between cerebrospinal fluid immune cells and tissue damage markers in multiple sclerosisSina Zaic, Theresa König, Markus Ponleitner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 20, 2025
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosisNik Krajnc, Markus Ponleitner, Fabian Föttinger, et al.
Frontiers in Neurology|May 1, 2024
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MSTobias Zrzavy, Kerstin Rieder, Viktoria Wuketich, et al.
Journal of Hematology & Oncology|April 18, 2015
EVI1 promotes tumor growth via transcriptional repression of MS4A3Gerwin Heller, Anna Rommer, Katarina Steinleitner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2021
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian studyGabriel Bsteh, Sophie Dürauer, Hamid Assar, et al.
Pageof 22

Showing results (161-170 of 220) with videos related to

Sort By:
Pageof 22
Multiple Sclerosis and Related Disorders|January 29, 2022
Trends in administrative prevalence of multiple sclerosis and utilization patterns of disease modifying drugs in GermanyJakob Holstiege, Manas K Akmatov, Kerstin Klimke, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|March 14, 2022
Olfactory threshold predicts treatment response in relapsing multiple sclerosisGabriel Bsteh, Harald Hegen, Klaus Berek, et al.
Neurology and Therapy|January 12, 2022
Therapy Switches in Fingolimod-Treated Patients with Multiple Sclerosis: Long-Term Experience from the German MS RegistryNiklas Frahm, Firas Fneish, David Ellenberger, et al.
Therapeutic Advances in Chronic Disease|August 11, 2021
Rituximab <i>versus</i> mitoxantrone: comparing effectiveness and safety in advanced relapsing multiple sclerosisTobias Zrzavy, Esther Daniels, Niklas Stuka, et al.
Journal of Neuroimmune Pharmacology : the Official Journal of the Society on Neuroimmune Pharmacology|November 22, 2015
Safety and Clinical Outcomes of Rituximab Treatment in Patients with Multiple Sclerosis and Neuromyelitis Optica: Experience from a National Online Registry (GRAID)P S Rommer, T Dörner, K Freivogel, et al.
Brain Communications|November 12, 2025
Dynamic relationship between cerebrospinal fluid immune cells and tissue damage markers in multiple sclerosisSina Zaic, Theresa König, Markus Ponleitner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|August 20, 2025
Serum neurofilament light chain and glial fibrillary acidic protein levels are associated with inner retinal layer thinning in multiple sclerosisNik Krajnc, Markus Ponleitner, Fabian Föttinger, et al.
Frontiers in Neurology|May 1, 2024
Immunophenotyping in routine clinical practice for predicting treatment response and adverse events in patients with MSTobias Zrzavy, Kerstin Rieder, Viktoria Wuketich, et al.
Journal of Hematology & Oncology|April 18, 2015
EVI1 promotes tumor growth via transcriptional repression of MS4A3Gerwin Heller, Anna Rommer, Katarina Steinleitner, et al.
Multiple Sclerosis (Houndmills, Basingstoke, England)|October 1, 2021
Humoral immune response after COVID-19 in multiple sclerosis: A nation-wide Austrian studyGabriel Bsteh, Sophie Dürauer, Hamid Assar, et al.
Pageof 22